What does the term A2 donor refer to, and is it a blood group A donor?

What is an A2 Donor?

An A2 donor refers to a blood group A donor with the A2 subtype, which expresses significantly lower levels of A antigen on cell surfaces compared to the more common A1 subtype, making A2 organs less immunogenic and potentially suitable for transplantation into blood group O or B recipients under specific conditions.

Understanding A2 Blood Subtype

The A2 subtype is a distinct variant within blood group A that differs fundamentally from the more common A1 subtype 1:

• A2 represents approximately 20% of all blood group A individuals 2, 3
• A2 expresses markedly lower levels of A antigen on vascular endothelium and cell surfaces compared to A1 donors 4, 1
• Three distinct renal A antigen expression patterns exist: Type 3+ (strong expression in A1 donors), Type 1+ (weaker expression in some A2 donors), and Type (+) (minimal expression in other A2 donors) 1

Clinical Significance in Transplantation

Crossing ABO Barriers

A2 kidneys can be successfully transplanted into blood group O and B recipients, expanding the donor pool for these patients who typically face longer waiting times 5, 2, 3:

• Blood group O patients have median waiting times exceeding 1,000 days, while A2 kidney allocation can significantly reduce this 2
• A2 organs are considered a "minor" antigen challenge compared to A1 or B organs, which represent "major" challenges 1

Critical Selection Criteria

Pre-transplant antibody titers are essential for determining transplant eligibility 4, 5, 2:

• IgG anti-A titers should be <1:8 for safe transplantation 4, 5
• IgM anti-A1 titers matter significantly: High IgM titers are associated with early allograft dysfunction, acute rejection, and thrombotic microangiopathy, even when IgG titers are low 4
• Plasmapheresis should be performed for patients with anti-A1 titers ≥1:8 to reduce hyperacute rejection risk 2

Clinical Outcomes

Long-term outcomes of A2 to O/B transplantation are excellent when proper selection criteria are followed 5, 2, 3:

• One-year graft survival rates of 93.3% have been reported 2
• Mean serum creatinine levels of 1.3-1.7 mg/dL at one year demonstrate excellent allograft function 2
• Hyperacute rejection occurs primarily in patients with high antibody titers who do not receive plasmapheresis 2

Important Caveats

A2 subtype determination requires specific testing beyond standard ABO typing 6, 7:

• Anti-A1 lectin testing is the traditional method, but molecular PCR-based methods provide more accurate subtype determination 5
• Mistyping can occur with lectin-based methods alone: One case of an A1O1 nonsecretor mistyped as A2 still resulted in successful transplantation, though this represents a significant risk 5
• Donor blood group A subtype testing should be performed when donation is planned to recipients with anti-A antibodies 6

The risk-benefit calculation differs from standard ABO-identical transplantation 4:

• Four out of seven patients (57%) in one series experienced early allograft dysfunction when high IgM titers were present despite low IgG titers 4
• Both IgG and IgM anti-A titers should be measured and considered in establishing center-specific selection criteria 4